title: Adynamic bone disease with negative aluminium staining in predialysis patients: prevalence and evolution after maintenance dialysis.
abstract: Aplastic bone disease (ABD) is a common form of renal osteodystrophy and is characterized by a defect in bone matrix formation and mineralization without an increase in osteoid thickness. The prevalence and pathogenesis of ABD in predialysis patients is largely unknown. We prospectively studied 92 unselected predialysis patients with a creatinine clearance < 10 ml/min/1.73 m2 and a mean age of 45 +/- 2 years (61 M, 31 F). None of the study patients had received any form of vitamin D therapy, and CaCO3 was the primary phosphate binder. Aplastic bone disease was observed in 30 (32%) patients. Stainable bone aluminium surface was < 3% in all ABD patients. Patients with ABD were older (52 +/- 3 versus 42 +/- 2 years; P < 0.01) and had reduced serum intact PTH compared to non-ABD patients (199 +/- 25 versus 561 +/- 87 pg/ml; P < 0.001). Patients with diabetes mellitus showed lower PTH values (179 +/- 31 versus 432 +/- 62 pg/ml; P < 0.001) and a lower incidence of advanced hyperparathyroidism bone lesions (16% versus 46%; P < 0.05) than non-diabetic patients. However, diabetes was not clearly associated with low bone turnover disease (56% in diabetics versus 41% in non-diabetics; P = 0.1). A second bone biopsy was obtained in eleven ABD patients after a period of 16.6 +/- 2.2 months on maintenance dialysis with a dialysate calcium of 7 mg/dl. Bone histology was unchanged in 10 patients, and one evolved to mild hyperparathyroidism. Trabecular bone volume did not change (22.7 +/- 1.7 versus 20.7 +/- 1.7%), and the stainable bone aluminium surface remained < 3%.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Nephrology Section, Hospital Universitario de Canarias, Tenerife, Spain.
authors.forename: D
authors.initials: D
authors.lastname: Hernandez
authors.forename: M T
authors.initials: MT
authors.lastname: Concepcion
authors.forename: V
authors.initials: V
authors.lastname: Lorenzo
authors.forename: M E
authors.initials: ME
authors.lastname: Martinez
authors.forename: A
authors.initials: A
authors.lastname: Rodriguez
authors.forename: E
authors.initials: E
authors.lastname: De Bonis
authors.forename: J M
authors.initials: JM
authors.lastname: Gonzalez-Posada
authors.forename: A J
authors.initials: AJ
authors.lastname: Felsenfeld
authors.forename: M
authors.initials: M
authors.lastname: Rodriguez
authors.forename: A
authors.initials: A
authors.lastname: Torres
mesh_terms: D000328:Adult; D000535:Aluminum / Q000378:metabolism*; D001842:Bone and Bones / Q000378:metabolism* / Q000473:pathology; D002119:Calcium Carbonate / Q000008:administration & dosage; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000209:etiology / Q000378:metabolism*; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood; D011446:Prospective Studies; D006435:Renal Dialysis / Q000009:adverse effects; D013194:Staining and Labeling / Q000379:methods
chemical_list: D010281:Parathyroid Hormone; D000535:Aluminum; D002119:Calcium Carbonate